Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats

European Journal of Pharmacology

Volumn 729, Issue 1, 2014, Pages 59-66

  Jones, Robert B ^a   Vickers, Steven P ^a   Cheetham, Sharon C ^a   Headland, Katie R ^a   Mark, Michael ^b   Klein, Thomas ^b  

^a RenaSci Ltd   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

Exendin 4; GLP 1; Glucose control; Linagliptin; Type 2 diabetes; Voglibose

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LINAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INOSITOL; PEPTIDE; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE; VENOM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN RELEASE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; WEIGHT REDUCTION; ZUCKER DIABETIC FATTY RAT; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DRUG EFFECTS; METABOLISM; TREATMENT OUTCOME; ZUCKER RAT;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HYPOGLYCEMIC AGENTS; INOSITOL; MALE; PEPTIDES; PURINES; QUINAZOLINES; RATS; RATS, ZUCKER; TREATMENT OUTCOME; VENOMS;

EID: 84894745919     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.02.004     Document Type: Article

References (38)

1. R. Aletti, and A. Cheng-Lai Linagliptin: the newest dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus Cardiol. Rev. 20 2012 45 51
2. American Diabetes Association Executive summary on standards of medical care in diabetes Diabetes Care 35 Suppl. 1 2012 S4 S10
3. J.P. Bantle Dietary fructose and metabolic syndrome and diabetes J. Nutr. 139 2009 1263S 1268S
4. A. Barnett DPP-4 inhibitors and their potential role in the management of type 2 diabetes Int. J. Clin. Pract. 60 2006 1454 1470 (Pubitemid 44560347)
5. A.H. Barnett Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy Adv. Ther. 28 2011 447 459
6. G.M. Bray Exenatide Am. J. Health Syst. Pharm. 63 2006 411 418 (Pubitemid 43334150)
7. D.X. Brown, and M. Evans Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective J. Nutr. Metabol. 2012 2012 10, Article ID 381713
8. X. Chen, Y. Zheng, and Y. Shen Voglibose (Basen, AO-128), one of the most important α-glucosidase inhibitors Curr. Med. Chem. 13 2006 109 116
9. R.S. Cvetković, and G.L. Plosker Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea) Drugs 67 2007 935 954 (Pubitemid 46607392)
10. J.A. Davidson Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors Cleve. Clin. J. Med. 76 2009 S28 S38
11. D. Drucker The biology of incretin hormones Cell Metab. 3 2006 153 165
12. G.J. Etgen, and B.A. Oldham Profiling of Zucker diabetic fatty Zucker rats in their progression to the overt diabetic state Metabolism 49 2000 684 688 (Pubitemid 30305272)
13. H. Fuchs, R. Binder, and A. Greischel Tissue distribution of the novel DPP-4 inhibitor BI1356 is dominated by saturable binding to its target in rats Biopharm. Drug Dispos. 30 2009 229 240
14. H. Fuder, P. Kleist, M. Birkel, A. Ehrlich, S. Emeklibas, W. Maslak, E. Stridde, N. Wetzelsberger, G. Wieckhorst, and P.W. Lücker The alphaglucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin Eur. J. Clin. Pharmacol. 53 1997 153 157 (Pubitemid 27491670)
15. B. Gallwitz Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes Diabetes Metab. Syndr. Obes. 6 2013 1 9
16. W. Gao, and W.J. Jusko Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kalizaki rats J. Pharmacol. Exp. Ther. 336 2011 881 890
17. B. Göke, H. Fuder, G. Wieckhorst, U. Theiss, E. Stridde, T. Littke, P. Kleist, R. Arnold, and P.W. Lücker Voglibose (AO-128) is an efficient alpha glucosidase inhibitor and mobilises the endogenous GLP-1 reserve Digestion 56 1995 493 501
18. U. Graefe-Mody, S. Retlich, and C. Friedrich Clinical pharmacokinetics and pharmacodynamics of linagliptin Clin. Pharmacokinet. 51 2012 411 427
19. C.M. Mack, C.X. Moore, C.M. Jodka, S. Bhavsar, J.K. Wilson, J.A. Hoyt, J.L. Roan, C. Vu, K.D. Laugero, D.G. Parkes, and A.A. Young Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures Int. J. Obes. 30 2006 1332 1340 (Pubitemid 44306514)
20. J.J. Meier, and M.A. Nauck Incretins and the development of type 2 diabetes Curr. Diab. Rep. 6 2006 194 201
21. Y. Moritoh, K. Takeuchi, and M. Hazama Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide levels by increasing its secretion and decreasing dipeptidly peptidase-4 activity in ob/ob mice J. Pharmacol. Exp. Ther. 329 2009 669 676
22. Y. Moritoh, K. Takeuchi, and M. Hazama Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice Diabetes Obes. Metab. 12 2010 224 233
23. T. Narita, H. Yokoyama, R. Yamashita, T. Sato, M. Hosoba, T. Morii, H. Fujita, K. Tsukiyama, and Y. Yamada Comparison of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients Diabetes Obes. Metab. 14 2012 283 287
24. G. Papa, C. Degano, M.P. Iurato, C. Licciardello, R. Maiorana, and C. Finocchiaro Macrovascular complication phenotypes in type 2 diabetic patients Cardiovasc. Diabetol. 12 2013 20 10.1186/1475-2840-12-20
25. D. Pérez-Tilve, L. González-Matías, B.A. Aulinger, M. Alvarez-Crespo, M. Gil-Lozano, E. Alvarez, A.M. Andrade-Olivie, M.H. Tschöp, D.A. D'Allessio, and F. Mallo Exendin-4 increases blood glucose levels acutely in rats by activation of the sympathetic nervous system Am. J. Physiol. Endocrinol. Metab. 298 2010 E1088 E1096
26. R.E. Pratley, and A. Salsali Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes Curr. Med. Res. Opin. 23 2007 919 931 (Pubitemid 46631495)
27. T. Rauch, U. Graefe-Mody, C.F. Deacon, A. Ring, J.J. Holst, H.J. Woerle, K.A. Dugl, and T. Heise Linagliptin increases incretin levels, lowers glucagon and improves glycaemic control in type 2 diabetes mellitus Diabetes Ther. 3 2012 10 10.1007/s13300-012-0010-y
28. C.W. Spellman Pathophysiology of type 2 diabetes: targeting islet cell dysfunction J. Am. Osteopath. Assoc. 110 2010 S2 S7
29. L. Thomas, M. Eckhardt, E. Langkopf, M. Tadayyon, F. Himmelsbach, and M. Mark (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-inazolin- 2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors J. Pharmacol. Exp. Ther. 325 2008 175 182 (Pubitemid 351439162)
30. L. Thomas, M. Tadayyon, and M. Mark Chronic treatment with the dipeptidly peptidase-4 inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3- methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] increases basal glucagon-like peptide-1 and improves glycaemic control in diabetic rodent models J. Pharmacol. Exp. Ther. 328 2009 556 563
31. J.F. Todd, and S.R. Bloom Incretins and other peptides in the treatment of diabetes Diabet. Med. 24 2007 223 232
32. S.P. Vickers, S.C. Cheetham, G.D. Birmingham, H.L. Rowley, K.R. Headland, K. Dickinson, R. Grempler, B. Hocher, M. Mark, and T. Klein Effects of the DPP-4 inhibitor linagliptin, in diet-induced obese rats: a comparison in naive and exenatide-treated animals Clin. Lab. 58 2012 787 799
33. J. White Efficacy and safety of incretin based therapies: clinical trial data J. Am. Pharm. Assoc. 49 2009 S30 S40
34. World Health Organisation, 2012, Diabetes fact sheet no. 312. 〈http://www.who.int/mediacentre/factsheets/fs312/en/ âŒ.
35. E.E. Wright Jr., A.H. Stonehouse, and R.M. Cuddihy In support of an early polypharmacy approach to the treatment of type 2 diabetes Diabetes Obes. Metab. 12 2010 929 940
36. M. Yamaguchi, T. Saji, S. Mita, K. Kulmatycki, Y.L. He, K. Furihata, and K. Sekiguchi Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes Int. Clin. Pharmacol. Ther. 51 2013 641 651
37. K. Yamazaki, T. Inoue, N. Yasuda, Y. Sato, T. Nagakura, O. Takenaka, R. Clark, T. Saeki, and I. Tanaka Comparison of the efficacies of a dipeptidyl peptidase IV inhibitor and alpha glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice J. Pharmacol. Sci. 104 2007 29 38 (Pubitemid 46790313)
38. A.A. Young, B.R. Gedulin, S. Bhavsar, N. Bodkin, C. Jodka, B. Hansen, and M. Denaro Glucose lowering and insulin sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta) Diabetes 48 1999 1026 1034